Real-time enrollment status for this her2-positive cancer clinical trial
Current Status
Active, Not Recruiting
Checked: April 17, 2026 at 3:43 AM UTC
| NCT Number | NCT04482309 |
| Recruiting Status | Active, Not Recruiting |
| Condition | HER2-positive Cancer |
| Phase | Clinical Trial |
| Target Enrollment | 468 participants |
| Active Locations | 22 sites in the US |
| Sponsor | AstraZeneca |
| Last Updated on CT.gov | April 9, 2026 (1 week ago) |
As of April 17, 2026: Clinical trial NCT04482309 is currently active_not_recruiting participants. This clinical trial study for her2-positive cancer is not currently accepting new participants at 22 locations across the United States. The study is sponsored by AstraZeneca. This status information is automatically verified from the official ClinicalTrials.gov registry.
No, NCT04482309 is currently active_not_recruiting. The study may resume recruiting in the future.
This trial is recruiting at 22 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT04482309 was last updated 1 week ago (April 9, 2026). HelloStudys verifies this status automatically.